^Curran, C. (September 2004). “Stimulant psychosis: systematic review”. The British Journal of Psychiatry185 (3): 196–204. doi:10.1192/bjp.185.3.196. PMID 15339823. http://bjp.rcpsych.org/content/185/3/196.long.
^Smart RG (1976). “Effects of legal restraint on the use of drugs: a review of empirical studies”. U.N. Bulletin on Narcotics28 (1): 55–65. PMID 1046373. http://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1976-01-01_1_page006.html.
^Srisurapanont, Manit; Ali, Robert; Marsden, John; Sunga, Agueda; Wada, Kiyoshi; Monteiro, Maristela (2003). “Psychotic symptoms in methamphetamine psychotic in-patients”. The International Journal of Neuropsychopharmacology6 (4): 347–352. doi:10.1017/S1461145703003675.
^ abSato, M.; Numachi, Y.; Hamamura, T. (1992). “Relapse of Paranoid Psychotic State in Methamphetamine Model of Schizophrenia”. Schizophrenia Bulletin18 (1): 115–122. doi:10.1093/schbul/18.1.115. http://schizophreniabulletin.oxfordjournals.org/content/18/1/115.full.pdf+html.
^Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. pp. 329.
^Yui, Kunio; Ikemoto, Shigenori; Goto, Kimihiko (2002). “Factors for Susceptibility to Episode Recurrence in Spontaneous Recurrence of Methamphetamine Psychosis”. Annals of the New York Academy of Sciences965 (1): 292–304. doi:10.1111/j.1749-6632.2002.tb04171.x.
^Alan F. Schatzberg, Charles B. Nemeroff (2009). The American Psychiatric Publishing Textbook of Psychopharmacology. The American Psychiatric Publishing. pp. 847–48. ISBN 978-1-58562-309-9. http://books.google.com/?id=Xx7iNGdV25IC&pg=PP1.
^Chen, Chih-Ken; Lin, Shih-Ku; Sham, Pak C.; Ball, David; Loh, El-Wui; Murray, Robin M. (2005). “Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis”. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics136B (1): 87–91. doi:10.1002/ajmg.b.30187.
^McIver C, McGregor C, Baigent M, Spain D, Newcombe D, on behalf of the Guidelines Development Working Party (pdf). Guidelines for the medical management of patients with methamphetamine-induced psychosis. Drug and Alcohol Services: South Australia, Government of South Australia. ISBN 0-9803130-1-5. http://www.sahealth.sa.gov.au/wps/wcm/connect/cbad29804178755b94d1ff67a94f09f9/Guidelines+methamphetamine-induced+psychosis-DASSA-Oct2013.pdf?MOD=AJPERES&CACHEID=cbad29804178755b94d1ff67a94f09f92014年6月4日閲覧。.
^Sarampote, Christopher S.; Efron, Lisa A.; Robb, Adelaide S.; Pearl, Phillip L.; Stein, Mark A. (2002). “Can Stimulant Rebound Mimic Pediatric Bipolar Disorder?”. Journal of Child and Adolescent Psychopharmacology12 (1): 63–67. doi:10.1089/10445460252943588. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477/.
^ abcThirthalli J., Vivek B. (2006). “Psychosis Among Substance Users”. Curr Opin Psychiatry19 (3): 239–245. doi:10.1097/01.yco.0000218593.08313.fd. http://www.medscape.com/viewarticle/528487_5.
^Elliott, Amber; Mahmood, Tashfeen; Smalligan, Roger D. (2012). “Cocaine Bugs: A Case Report of Cocaine-Induced Delusions of Parasitosis”. The American Journal on Addictions21 (2): 180–181. doi:10.1111/j.1521-0391.2011.00208.x.
^DiSclafani A, Hall RC, Gardner ER (October 1981). “Drug-induced psychosis: emergency diagnosis and management”. Psychosomatics22 (10): 845–50, 855. doi:10.1016/S0033-3182(81)73092-5. PMID 7313045.
^Auriel, Eitan; Hausdorff, Jeffrey M.; Giladi, Nir (2009). “Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders”. Clinical Neuropharmacology32 (2): 75–81. doi:10.1097/WNF.0b013e318170576c.
^Abramowicz MJ, Van Haecke P, Demedts M, Delcroix M (September 2003). “Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation”. Eur. Respir. J.22 (3): 560–2. doi:10.1183/09031936.03.00095303. PMID 14516151. http://erj.ersjournals.com/content/22/3/560.full.
^Morton WA, Stockton GG (October 2000). “Methylphenidate Abuse and Psychiatric Side Effects”. Primary Care Companion to the Journal of Clinical Psychiatry2 (5): 159–164. PMC: 181133. PMID 15014637. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC181133/.
^Spensley J, Rockwell D (April 1972). “Psychosis during Methylphenidate Abuse”. New England Journal of Medicine286: 880–1. doi:10.1056/NEJM197204202861607. PMID 5061074.
^Ashton H, Gallagher P, Moore B (September 2006). “The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder”. J. Psychopharmacol. (Oxford)20 (5): 602–10. doi:10.1177/0269881106061710. PMID 16478756.
^Kimko HC, Cross JT, Abernethy DR (December 1999). “Pharmacokinetics and clinical effectiveness of methylphenidate”. Clin Pharmacokinet37 (6): 457–70. doi:10.2165/00003088-199937060-00002. PMID 10628897.
^Cherland E, Fitzpatrick R (October 1999). “Psychotic side effects of psychostimulants: a 5-year review”. Can J Psychiatry44 (8): 811–3. PMID 10566114.
^MacKenzie, Lynn E.; Abidi, Sabina; Fisher, Helen L.; et al. (2016). “Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness”. Pediatrics137 (1): e20152486. doi:10.1542/peds.2015-2486. PMID 26719291. https://doi.org/10.1542/peds.2015-2486.
^Dafny N; Yang PB. (15 February 2006). “The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: A review of its locomotor effects.”. Brain research bulletin.68 (6): 393–405. doi:10.1016/j.brainresbull.2005.10.005. PMID 16459193.
^Rosenfeld AA (February 1979). “Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report”. Am J Psychiatry136 (2): 226–8. PMID 760559.
^Cohen D, Leo J, Stanton T, et al (2002). “A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study”. Ethical Hum Sci Serv4 (3): 189–209. PMID 15278983. http://www.ingentaconnect.com/content/springer/ehss/2002/00000004/00000003/art00002.
^Schwartz RH, Rushton HG (May 2004). “Stuttering priapism associated with withdrawal from sustained-release methylphenidate”. J. Pediatr.144 (5): 675–6. doi:10.1016/j.jpeds.2003.12.039. PMID 15127013. http://www.jpeds.com/article/S0022-3476(04)00022-8/fulltext.
^Garland EJ (1998). “Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats”. J. Psychopharmacol. (Oxford)12 (4): 385–95. doi:10.1177/026988119801200410. PMID 10065914.
^Hedges, D. W.; F. L. Woon, S. P. Hoopes (September 2009). “Caffeine-induced psychosis.”. CNS Spectrums14 (3): 127–9. PMID 19407709.
^Cerimele, J. M.; A. P. Stern, D. Jutras-Aswad (September 2010). “Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia.”. American Journal of Psychiatry167 (3): 353. doi:10.1176/appi.ajp.2009.09101456. PMID 20194494.
^“Caffeine and psychiatric symptoms: a review”. J Okla State Med Assoc97 (12): 538–42. (December 2004). PMID 15732884.
^世界保健機関、(翻訳)融道男、小見山実、大久保善朗、中根允文、岡崎祐士『ICD-10精神および行動の障害:臨床記述と診断ガイドライン』医学書院、2005年、新訂版。ISBN 978-4-260-00133-5。、世界保健機関 (1992) (pdf). The ICD-10 Classification of Mental and Behavioural Disorders : Clinical descriptions and diagnostic guidelines (blue book). World Health Organization. http://www.who.int/classifications/icd/en/bluebook.pdf. 英語原本では F1x.5 Psychotic disorder (pp72-73) の項。
^ abアレン・フランセス『精神疾患診断のエッセンス―DSM-5の上手な使い方』金剛出版、2014年3月、121、134。ISBN 978-4772413527。、Essentials of Psychiatric Diagnosis, Revised Edition: Responding to the Challenge of DSM-5®, The Guilford Press, 2013.
… associated with stimulants are reviewed in further detail separately. Psychosis has occurred with stimulant abuse and in treatment with stimulants in patients with a vulnerability to psychosis characterized …
… including cocaine, phencyclidine, and synthetic cathinone ('bath salts) Factors that may be useful in distinguishing methamphetamine-induced psychosis from other causes include: Age of onset – Earlier …
3. 小児や青年の注意欠陥多動性障害治療薬の薬理学pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents [show details]
… treatment of priapism are discussed separately. Psychosis – Children and adolescents treated with stimulant medications rarely may develop psychotic symptoms (eg, hallucinations, delusional thinking …
…a theoretically increased risk of psychosis when treated with stimulants; cases have been reported in schizotypal personality disorder patients treated with a stimulant for co-occurring ADHD , but appear …
… case with such prolonged symptoms. While psychosis is a common finding in amphetamine abuse, seizures and chest pain are more commonly seen with pure stimulants, such as cocaine . Pure hallucinogens, such …